Cutaneous Leishmaniasis: Treatment Options and Possibilities for Drug Repurposing Submitted: Jul 21, 2019 Accepted: Oct 25, 2019 Published online: Nov 12, 2019


Aziz Alsohaimi


Leishmaniasis is a tropical disease caused by aprotozoan which is obligate intracellular parasite belongs to the genus Leishmania. There are 3 forms of the disease: visceral leishmaniasis, cutaneous leishmaniasis which is the most common, and mucocutaneous leishmaniasis. The most important compounds used to treat leishmaniasis were meglumine antimoniate (e.g. glucantime), sodium stibogluconate (e.g. pentostam) and pentavalent antimonials. There are other drugs that may be used such as pentamidine and amphotericin B. Until now, the pentavalent antimonial compounds remain the corner stone in the treatment of cutaneous leishmaniasis although this group possesses high degree of toxicity.
Other treatment options include the pentamidines and liposomal amphotericin B (AmBisome). Combination therapies using AmBisome and miltefosine are another effective alternative to antimonial compounds. Other latest therapeutic options include photodynamic therapy, tamoxifen and imiquimod. The proper choice of antileishmanial therapy depends on the geographic location, host immune status, availability of the drug, and expertise of the treating physician. The present review summarizes the current treatment options available for cutaneous leishmaniasis as well as some drugs on the horizon that show promising results in the treatment of cutaneous leishmaniasis.


Download data is not yet available.



Cutaneous leishmaniasis, Pentavalent antimonials, Pentamidine, Amphotericin B, AmBisome, Miltefosine

How to Cite
Alsohaimi, A. (2019). Cutaneous Leishmaniasis: Treatment Options and Possibilities for Drug Repurposing: Submitted: Jul 21, 2019 Accepted: Oct 25, 2019 Published online: Nov 12, 2019. Advances in Medicine and Medical Research, 2(1), 9-19.
Original Articles


Control of the Leishmaniasis. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases; Geneva. 22–26 March 2010.

Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013; 14(1):53–63.

Bailey F, Mondragon-Shem K, Hotez P, Ruiz-Postigo JA, Al-Salem W, Acosta-Serrano Á, Molyneux DH. A new perspective on cutaneous leishmaniasis-Implications for global prevalence and burden of disease estimates. PLoS Negl Trop Dis. 2017;11(8):e0005739.

Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther. 2010;8(4):419–33.

Sousa AQ, Pompeu MM, Frutuoso MS, Lima JW, Tinel JM, Pearson RD. Press imprint smear: a rapid, simple, and cheap method for the diagnosis of cutaneous Leishmaniasis Caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg. 2014;91(5):905–7.

Kar K. Serodiagnosis of leishmaniasis. Crit Rev Microbiol. 1995;21(2):123–52.7. Antonio Lde F, Fagundes A, Oliveira RV, Pinto PG, Bedoya–Pacheco SJ, Vasconcellos Ede C1, Valete–Rosalino MC, Lyra MR, Passos SR, Pimentel MI, Schubach Ade O. Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo. 2014;56(5):375–80.

Passos VM, Barreto SM, Romanha AJ, Krettli AU, Volpini AC, Lima e Costa MF. American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment. Bull World Health Organ. 2000;78(8):968–74.

Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am J Trop Med Hyg. 1991;44(3):260–71.

Schnorr D, Muniz AC, Passos S, Guimaraes LH, Lago EL, Bacellar O, Glesby MJ, Carvalho EM. IFN–gamma production to leishmania antigen supplements the leishmania skin test in identifying exposure to L. braziliensis infection. PLoS Negl Trop Dis. 2012;6(12):e1947.

Alimohammadian MH, Jones SL, Darabi H, Riazirad F, Ajdary S, Shabani A, Rezaee MA, Mohebali M, Hosseini Z, Modabber F. Assessment of interferon–gamma levels and leishmanin skin test results in persons recovered for leishmaniasis. Am J Trop Med Hyg. 2012;87(1):70–5.

Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol.2007;45(1):21–5.

Cruz I, Millet A, Carrillo E, Chenik M, Salotra P, Verma S, Veland N, Jara M, Adaui V, Castrillón C, Arévalo J, Moreno J, Cañavate C. An approach for interlaboratory comparison of conventional and real–time PCR assays for diagnosis of human leishmaniasis. Exp Parasitol. 2013;134(3):281–9.

Odiwuor SO, Saad AA, De Doncker S, Maes I, Laurent T, El Safi S, Mbuchi M, Büscher P, Dujardin JC, Van der Auwera G. Universal PCR assays for the differential detection of all Old World Leishmania species. Eur J Clin Microbio Infect Dis. 2011; 30(2):209–18.

Toz SO, Culha G, Zeyrek FY, Ertabaklar H, Alkan MZ, Vardarli AT, Gunduz C, Ozbel Y. A real–time ITS1 PCR based method in the diagnosis and species identification of Leishmania parasite from human and dog clinical samples in Turkey. PLoS Negl Trop Dis. 2013;7(5): e2205.

Monroy–Ostria A, Nasereddin A, Monteon VM, Guzman–Bracho C, Jaffe CL. ITS1 PCR–RFLP diagnosis and characterization of Leishmania in clinical samples and strains from cases of human cutaneous leishmaniasis in states of the Mexican Southeast. Interdiscip Perspect Infect Dis. 2014; 2014:607287.

Satow MM, Yamashiro–Kanashiro EH, Rocha MC, Oyafuso LK, Soler RC, Cotrim PC, Lindoso JA.Applicability of kDNA–PCR for routine diagnosis of American tegumentary leishmaniasis in a tertiary reference hospital. Rev Inst Med Trop Sao Paulo. 2013;55(6):393–9.

Jara M, Adaui V, Valencia BM, Martinez D, Alba M, Castrillon C, Cruz M, Cruz I, Van der Auwera G, Llanos–Cuentas A, Dujardin JC, Arevalo J. Real–time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters. J Clin Microbiol. 2013;51(6):1826–33.

Mugasa CM, Laurent T, Schoone GJ, Basiye FL, Saad AA, El Safi S, Kager PA, Schallig HD. Simplified molecular detection of Leishmania parasites in various clinical samples from patients with leishmaniasis. Parasit Vectors. 2010; 3(1):13.

Mugasa CM, Deborggraeve S, Schoone GJ, Laurent T, Leeflang MM, Ekangu RA, El Safi S, Saad AF, Basiye FL, De Doncker S, Lubega GW, Kager PA, Büscher P, Schallig HD. Accordance and concordance of PCR and NASBA followed by oligochromatography for the molecular diagnosis of Trypanosoma brucei and Leishmania. Trop Med Int Health. 2010;15(7):800–5.

Saad AA, Ahmed NG, Osman OS, Al–Basheer AA, Hamad A, Deborggraeve S, Büscher P, Schoone GJ, Schallig HD, Laurent T, Haleem A, Osman OF, Eltom AM, Elbashir MI, El–Safi S. Diagnostic accuracy of the Leishmania OligoC–TesT and NASBA–oligochromatography for diagnosis of leishmaniasis in Sudan. PLoS Negl Trop Dis. 2010;4(8):e776.

Adams ER, Gomez MA, Scheske L, Rios R, Marquez R, Cossio A, Albertini A, Schallig H, Saravia NG. Sensitive diagnosis of cutaneous leishmaniasis by lesion swab sampling coupled to qPCR. Parasitology. 2014;141(14):1891–7.

Pratlong F, Dereure J, Ravel C, Lami P, Balard Y, Serres G, Lanotte G, Rioux JA, Dedet JP. Geographical distribution and

Alsohaimi A.© 2019, The AuthorsAdv Med Med Res, 2019; 2(1):9-19ISSN: 2535-221018Cutaneous leishmaniasis: treatment options and possibilities for drug repurposingepidemiological features of Old World cutaneous leishmaniasis foci, based on the isoenzyme analysis of 1048 strains. Trop Med Int Health. 2009;14(9):1071–85.

Hernández C, Alvarez C, González C, Ayala MS, León CM, Ramírez JD. Identification of Six New World Leishmania species through the implementation of a High–Resolution Melting (HRM) genotyping assay. Parasit Vectors. 2014;7:501.

Lima EB, Porto C, Motta JCO, Sampaio RNR. Treatment of American cutaneous leishmaniasis. An Bras Dermatol. 2007;82(2):111–24.

Croft SL, Barret MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 2005;21:508–12.

Zutshi S, Kumar S, Chauhan P, Bansode Y, Nair A, Roy S, Sarkar A, Saha B. Anti–Leishmanial Vaccines: Assumptions, Approaches, and Annulments. Vaccines (Basel). 2019;7(4). pii: E156

Mohebali M, Nadim A, Khamesipour A. An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines. Acta Trop. 2019;200:105173.

Pijpers J, den Boer ML, Essink DR, Ritmeijer K. The safety and efficacy of miltefosine in the long–term treatment of post–kala–azar dermal leishmaniasis in South Asia – A review and meta–analysis. PLoS Negl Trop Dis. 2019;13(2):e0007173.

Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, Andrade CA. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 2011;118(2):87–96.

Hodiamont CJ, Kager PA, Bart A, de Vries HJ, van Thiel PP, Leenstra T, de Vries PJ, van Vugt M, Grobusch MP, van Gool T. Species–directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Trop Dis. 2014;8(5):e2832

Van der Auwera G, Dujardin J. Species typing in dermal leishmaniasis. Clin Microbiol Rev. 2015; 28:265–294.

WHO. Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the control of leishmaniases; 22–26 March 2010; Geneva. Geneva, Switzerland: World Health Organization; 2010. WHO technical report series no. 949.

Blum J, Buffet P, Visser L, Harms G, Bailey MS, Caumes E, Clerinx J, van Thiel PP, Morizot G, Hatz C, Dorlo TP, Lockwood DN. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J Travel Med. 2014;21(2):116–29.

Morizot G, Kendjo E, Mouri O, Thellier M, Pérignon A, Foulet F, Cordoliani F, Bourrat E, Laffitte E, Alcaraz I, Bodak N, Ravel C, Vray M, Grogl M, Mazier D, Caumes E, Lachaud L, Buffet PA; Cutaneous Leishmaniasis French Study Group. Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis. 2013;57(3):370–80.

WHO Model List of Essential Medicines (19th List). World Health Organization. April 2015. Archived from the original on 13 December 2016. Retrieved 8 December 2018.

Grela E, Piet M, Luchowski R, Grudzinski W, Paduch R, Gruszecki WI. Imaging of human cells exposed to an antifungal antibiotic amphotericin B reveals the mechanisms associated with the drug toxicity and cell defense. Sci Rep. 2018;8(1):14067.

Davidson R, diMartino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R. Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1996; 22 (6): 938–43.

Goyonlo V, Vosoughi E, Kiafar B. Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis. Indian J Dermatol. 2014; 59:631.

Porcheddu A, Giacomelli G, De Luca L. New pentamidine analogues in medicinal chemistry. Curr Med Chem. 2012;19(34):5819–36.

American Society of Health–System Pharmacists (26 February 2016). "Miltefosine Monograph for Professionals". Archived from the original on 17 November 2016. Retrieved 16 November 2018.

Bermann JJ. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol. 2008;4(9): 1209–16.

Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg. 2006;100(1): S41–4.

Cabrera–Serra MG, Lorenzo–Morales J, Romero M, Valladares B, Pinero JE. In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species. Parasitol Res. 2007; 11(5): 1155–7.

Cabrera–Serra MF, Valladares B, Pinero JE. In vivo activity of perifosine against Leishmania amazonensis. Acta Trop. 2008;108(1): 20–5.

Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S. Orally effective drugs for Kala–azar (visceral leishmaniasis): focus on miltefosine and sitamaquine. J Assoc Physcians India. 2003; 51:686–90.

Eid Rodríguez D, San Sebastian M, Pulkki–Brännström AM. "Cheaper and better": Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first–line treatment for cutaneous leishmaniasis in Bolivia. PLoS Negl Trop Dis. 2019;13(11):e0007788.

Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G: Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol. 2003;149(66):57–8.

Taylor LA, Gormley R, Kovarik C. Leishmania tropica: Combined debulking and imiquimod for the treatment of nonresponsive cutaneous leishmaniasis. J Am Acad Dermatol. 2017;76(1):e13–e14.

Sauder DN. Imiquimod: Modes of action. Br J Dermatol. 2003;149:5–8.

Miller RL, Gerster JF, Owens ML, Slade HB, Tomai M.

Alsohaimi A.Cutaneous leishmaniasis: treatment options and possibilities for drug repurposing© 2019, The AuthorsAdv Med Med Res, 2019; 2(1):9-19ISSN: 2535-221019Imiquimod applied topically: A novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21(1):1–14.

Trinconi CT, Reimão JQ, Yokoyama–Yasunaka JKU, Miguel DC, Uliana SRB. Combination Therapy with Tamoxifen and Amphotericin B in Experimental Cutaneous Leishmaniasis Antimicrob Agents Chemother. 2014;58(5):2608–2613.

Trinconi CT, Reimão JQ, Coelho AC, Uliana SRB. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. J Antimicrob Chemoth. 2016;71(5):1314–1322

Miguel DC, Zauli–Nascimento RC, Yokovama–Yasunaka JK, Katz S, Barbieri CL, Uliana SR. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother. 2009; 63(2): 365–8.

van der Snoek E, Robinson D, van Hellemond J, Neumann H. A review of photodynamic therapy in cutaneous leishmaniasis. J Eur Acad Dermatol Venereol. 2008;22(8):918–22.

Enk CD, Nasereddin A, Alper R, Dan–Goor M, Jaffe CL, Wulf HC. Cutaneous leishmaniasis responds to daylight–activated photodynamic therapy: proof of concept for a novel self–administered therapeutic modality. Br J Dermatol. 2015;172(5):1364–70.

Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis. 2012;6(6):e1674.

Emiliano YSS and Almeida–Amaral EE. Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis. J Nat Prod. 2018;81(8):1910–1913.

Hendrickx S, Van den Kerkhof M, Mabille D, Cos P, Delputte P, Maes L. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. PLoS Negl Trop Dis. 2017;11(5): e0005620.

Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos–Cuentas A, Pollack H. Role of Imiquimod and Parenteral Meglumine Antimoniate in the Initial Treatment of Cutaneous Leishmaniasis, Clinical Infect Dis. 2007; 44(12):1549–1554.